Tweet
Hum Vaccin Immunother. 2016 Jan 11:0. [Epub ahead of print]
A Systematic Review of the Efficacy of Live Attenuated Influenza Vaccine Upon Revaccination of Children.
Caspard H1, Heikkinen T2, Belshe RB3, Ambrose CS1.
Author information
Abstract
Four randomized, double-blind, placebo-controlled studies in 6090 children that investigated the efficacy of live attenuated influenza vaccine (LAIV) upon revaccination of children against laboratory-confirmed cases of influenza in consecutive seasons were reviewed. The efficacy in season 2 of LAIV administered over 2 consecutive seasons was 86.7% (95 % CI: 76.8%, 92.4%) against strains antigenically similar to those contained in the vaccine. The additional efficacy of LAIV administered in season 2 compared to LAIV recipients in season 1 only was 58.4% (28.3%, 75.9%). LAIV administered over 2 consecutive seasons also was more efficacious than was LAIV administered in season 2 only (relative efficacy: 53.9% [17.4%, 74.3%]). Residual efficacy of LAIV administered in season 1 only compared to placebo administered in two consecutive seasons was 56.4% (37.0%, 69.8%). This review did not find any evidence of decreasing efficacy of LAIV when administered during 2 consecutive seasons.
KEYWORDS:
Children; efficacy; live attenuated influenza vaccine; repeat vaccination; revaccination.
PMID: 26751513 [PubMed - as supplied by publisher]
A Systematic Review of the Efficacy of Live Attenuated Influenza Vaccine Upon Revaccination of Children.
Caspard H1, Heikkinen T2, Belshe RB3, Ambrose CS1.
Author information
Abstract
Four randomized, double-blind, placebo-controlled studies in 6090 children that investigated the efficacy of live attenuated influenza vaccine (LAIV) upon revaccination of children against laboratory-confirmed cases of influenza in consecutive seasons were reviewed. The efficacy in season 2 of LAIV administered over 2 consecutive seasons was 86.7% (95 % CI: 76.8%, 92.4%) against strains antigenically similar to those contained in the vaccine. The additional efficacy of LAIV administered in season 2 compared to LAIV recipients in season 1 only was 58.4% (28.3%, 75.9%). LAIV administered over 2 consecutive seasons also was more efficacious than was LAIV administered in season 2 only (relative efficacy: 53.9% [17.4%, 74.3%]). Residual efficacy of LAIV administered in season 1 only compared to placebo administered in two consecutive seasons was 56.4% (37.0%, 69.8%). This review did not find any evidence of decreasing efficacy of LAIV when administered during 2 consecutive seasons.
KEYWORDS:
Children; efficacy; live attenuated influenza vaccine; repeat vaccination; revaccination.
PMID: 26751513 [PubMed - as supplied by publisher]